Copyright
©The Author(s) 2017.
World J Hepatol. May 18, 2017; 9(14): 645-656
Published online May 18, 2017. doi: 10.4254/wjh.v9.i14.645
Published online May 18, 2017. doi: 10.4254/wjh.v9.i14.645
Organ at risk | 3 fraction (RAS trial[102]) | 5 fraction (RTOG 1112[103]) | QUANTEC (1.8-2 Gy per fraction)[104] | Toxicity |
Liver excluding CTV | 700 mL < 15 Gy | V 10 < 70% | D mean < 30 Gy | Radiation induced liver dysfunction |
Esophagus | D 1 mL < 21 Gy | D 0.5 mL < 32 Gy | V 35 < 50% | Esophagitis |
Stomach | D 1 mL < 21 Gy | D 0.5 mL < 30 Gy | D 100 < 35 Gy | Ulceration |
Kidney | D 35% < 15 Gy | D mean < 10 Gy | D mean < 28 Gy (1.8-2 Gy per fraction) | Renal dysfunction |
Bowel and duodenum | D 1 mL < 21 Gy | D 0.5 mL < 30 Gy | D 45 < 195 cc | Enteritis/fistula |
Spinal cord | Dmax < 18 Gy | D 0.5 mL < 25 Gy | Dmax = 45 | Myelopathy |
Heart | D 1 mL, 30 Gy | D 30 mL < 30 Gy | V 25 < 10% | Pericarditis |
- Citation: Lock MI, Klein J, Chung HT, Herman JM, Kim EY, Small W, Mayr NA, Lo SS. Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World J Hepatol 2017; 9(14): 645-656
- URL: https://www.wjgnet.com/1948-5182/full/v9/i14/645.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i14.645